Editorial
Metabolic dysfunction-associated steatohepatitis (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) require urgent attention by primary care physicians and endocrinologists
La esteatohepatitis asociada a disfunción metabólica (MASLD) y la esteatohepatitis asociada a disfunción metabólica (MASH) requieren atención urgente por parte de médicos de atención primaria y endocrinólogos
Didac Mauricioa,b,
, Javier Escaladac,d, Antonio Péreza,e, Manuel Romero-Gómezf, Kenneth Cusig, Zobair M. Younoussih,i, Jeffrey V. Lazarusi,j,k,l
Corresponding author
a Department of Endocrinology & Nutrition, CIBERDEM – IR Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
b Faculty of Medicine, University of Vic & Central University of Catalonia, Vic, Spain
c Department of Endocrinology & Nutrition, Clínica Universidad de Navarra, Pamplona, Spain
d Fundación de la Sociedad Española de Endocrinología y Nutrición, Madrid, Spain
e Sociedad Española de Diabetes, Madrid, Spain
f Digestive Diseases Department & CIBEREHD, Virgen del Rocío University Hospital, Institute of Biomedicine of Seville (HUVR/CSIC/US), University of Seville, Seville, Spain
g Division of Endocrinology, Diabetes & Metabolism, University of Florida, Gainesville, USA
h Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia, USA
i The Global NASH Council, Washington, DC, USA
j Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain
k Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain
l CUNY Graduate School of Public Health and Health Policy (CUNY SPH), New York, NY, USA
Ver más